STEFANIZZI, CATERINA
STEFANIZZI, CATERINA
DIPARTIMENTO DI MEDICINA MOLECOLARE
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
2010 Latagliata, R; Breccia, M; Carmosino, I; Cannella, L; De Cuia, R; Diverio, D; Frustaci, A; Loglisci, G; Mancini, M; Santopietro, M; Stefanizzi, Caterina; Volpicelli, P; Vozella, F; Alimena, Giuliana
Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.
2014 Breccia, M; De Propris, Ms; Minotti, C; Stefanizzi, Caterina; Raponi, Sara; Colafigli, G; Latagliata, R; Guarini, Anna; Foa, Roberto
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
2009 Massimo, Breccia; Laura, Cannella; Stefanizzi, Caterina; Michelina, Santopietro; Rosa De, Cuia; Daniela, Diverio; Alimena, Giuliana
ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN VERY ELDERLY PATIENTS (> 70 YEARS)
2010 R., Latagliata; P., Finsinger; M., Breccia; C., Minotti; I., Carmosino; L., Cannella; P., Volpicelli; F., Vozella; Stefanizzi, Caterina; G., Loglisci; Cimino, Giuseppe; Foa, Roberto
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
2009 M., Breccia; R., Latagliata; L., Cannella; I., Carmosino; R., De Cuia; A., Frustaci; Stefanizzi, Caterina; M., Santopietro; Alimena, Giuliana
Ara-C, idarubicine and Gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients
2012 Saveria, Capria; Silvia Maria, Trisolini; Clara, Minotti; Stefanizzi, Caterina; Luisa, Cardarelli; Claudio, Cartoni; Daniela, Diverio; Maria Stefania De, Propris; Marco, Mancini; Micozzi, Alessandra; Foa, Roberto; Meloni, Giovanna
Biologic and clinical significance of CD34 expression in acute promyelocytic leukemia
2007 M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; Guarini, Anna; M. S., De Propris; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience
2008 Massimo, Breccia; Laura, Cannella; Annamaria, Frustaci; Stefanizzi, Caterina; Anna, Levi; Alimena, Giuliana
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems
2008 M., Breccia; L., Cannella; A., Frustaci; Stefanizzi, Caterina; G. M., D'Elia; Alimena, Giuliana
Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients
2009 Massimo, Breccia; Anna Maria, Frustaci; Laura, Cannella; Stefanizzi, Caterina; Roberto, Latagliata; Claudio, Cartoni; Daniela, Diverio; Guarini, Anna; R., Nanni; Angela, Rago; Cimino, Giuseppe; Alimena, Giuliana
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas
2023 Autore, Francesco; Fresa, Alberto; Innocenti, Idanna; Principe, Maria Ilaria Del; Maglione, Raffaele; Stefanizzi, Caterina; Pelliccia, Sabrina; Romeo, Azzurra; Cimino, Giuseppe; Papa, Elena; Padua, Laura De; Andriani, Alessandro; Mengarelli, Andrea; Tafuri, Agostino; Ditto, Concetta; Mauro, Francesca Romana; Del Poeta, Giovanni; Laurenti, Luca
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
2010 Breccia, M; Cannella, L; Stefanizzi, Caterina; Latagliata, R; Nanni, M; Diverio, D; Santopietro, M; Federico, V; Alimena, Giuliana
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance
2009 Laura, Cannella; Massimo, Breccia; Stefanizzi, Caterina; Napoleone, Laura; Michela, Santopietro; Alimena, Giuliana
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results
2009 Roberto, Latagliata; Angela, Rago; Antonio, Spadea; Santoro, Cristina; Ida, Carmosino; Massimo, Breccia; Napoleone, Laura; Angelo, Fama; Francesca, Biondo; Paola, Volpicelli; Federico, Vozella; Stefanizzi, Caterina; Maria Concetta, Petti; Alimena, Giuliana; Mazzucconi, Maria Gabriella
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia
2008 Massimo, Breccia; Stefanizzi, Caterina; Laura, Cannella; Roberto, Latagliata; Anna Maria, Frustaci; Ida, Carmosino; Michelina, Santopietro; Alimena, Giuliana
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia
2007 Corrado, Girmenia; Eleonora, Russo; Ida, Carmosino; Massimo, Breccia; Francesco, Dragoni; Roberto, Latagliata; Sergio, Mecarocci; Salvatore Giacomo, Morano; Stefanizzi, Caterina; Alimena, Giuliana
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: AN IMMUNOMODULATORY EFFECT?
2009 Breccia, M; Cannella, L; Stefanizzi, Caterina; Carotti, A; Santopietro, M; Alimena, Giuliana
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
2008 M., Breccia; Muscaritoli, Maurizio; L., Cannella; Stefanizzi, Caterina; A., Frustaci; Alimena, Giuliana
Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia
In corso di stampa Chisini, Marta; Stefanizzi, Caterina; Ceglie, Teresa; Raponi, Sara; Vozella, Federico; Colafigli, Gioia; Salaroli, Adriano; D'Angiò, Mariella; Mancini, Marco; Diverio, Daniela; Breccia, Massimo; Mancini, Francesca; Minotti, Clara; Trisolini, Silvia; Capria, Saveria; Testi, Anna Maria; Guarini, Anna; Latagliata, Roberto; De Propris, Maria Stefania; Foa, Roberto
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
2009 Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. | 2010 | Latagliata, R; Breccia, M; Carmosino, I; Cannella, L; De Cuia, R; Diverio, D; Frustaci, A; Loglisci, G; Mancini, M; Santopietro, M; Stefanizzi, Caterina; Volpicelli, P; Vozella, F; Alimena, Giuliana | |
| Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. | 2014 | Breccia, M; De Propris, Ms; Minotti, C; Stefanizzi, Caterina; Raponi, Sara; Colafigli, G; Latagliata, R; Guarini, Anna; Foa, Roberto | |
| Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease | 2009 | Massimo, Breccia; Laura, Cannella; Stefanizzi, Caterina; Michelina, Santopietro; Rosa De, Cuia; Daniela, Diverio; Alimena, Giuliana | |
| ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN VERY ELDERLY PATIENTS (> 70 YEARS) | 2010 | R., Latagliata; P., Finsinger; M., Breccia; C., Minotti; I., Carmosino; L., Cannella; P., Volpicelli; F., Vozella; Stefanizzi, Caterina; G., Loglisci; Cimino, Giuseppe; Foa, Roberto | |
| Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal | 2009 | M., Breccia; R., Latagliata; L., Cannella; I., Carmosino; R., De Cuia; A., Frustaci; Stefanizzi, Caterina; M., Santopietro; Alimena, Giuliana | |
| Ara-C, idarubicine and Gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients | 2012 | Saveria, Capria; Silvia Maria, Trisolini; Clara, Minotti; Stefanizzi, Caterina; Luisa, Cardarelli; Claudio, Cartoni; Daniela, Diverio; Maria Stefania De, Propris; Marco, Mancini; Micozzi, Alessandra; Foa, Roberto; Meloni, Giovanna | |
| Biologic and clinical significance of CD34 expression in acute promyelocytic leukemia | 2007 | M., Breccia; R., Latagliata; I., Carmosino; L., Cannella; Guarini, Anna; M. S., De Propris; D., Diverio; A., Frustaci; Stefanizzi, Caterina; Cimino, Giuseppe; LO COCO, Francesco | |
| Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience | 2008 | Massimo, Breccia; Laura, Cannella; Annamaria, Frustaci; Stefanizzi, Caterina; Anna, Levi; Alimena, Giuliana | |
| Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems | 2008 | M., Breccia; L., Cannella; A., Frustaci; Stefanizzi, Caterina; G. M., D'Elia; Alimena, Giuliana | |
| Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients | 2009 | Massimo, Breccia; Anna Maria, Frustaci; Laura, Cannella; Stefanizzi, Caterina; Roberto, Latagliata; Claudio, Cartoni; Daniela, Diverio; Guarini, Anna; R., Nanni; Angela, Rago; Cimino, Giuseppe; Alimena, Giuliana | |
| Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas | 2023 | Autore, Francesco; Fresa, Alberto; Innocenti, Idanna; Principe, Maria Ilaria Del; Maglione, Raffaele; Stefanizzi, Caterina; Pelliccia, Sabrina; Romeo, Azzurra; Cimino, Giuseppe; Papa, Elena; Padua, Laura De; Andriani, Alessandro; Mengarelli, Andrea; Tafuri, Agostino; Ditto, Concetta; Mauro, Francesca Romana; Del Poeta, Giovanni; Laurenti, Luca | |
| Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. | 2010 | Breccia, M; Cannella, L; Stefanizzi, Caterina; Latagliata, R; Nanni, M; Diverio, D; Santopietro, M; Federico, V; Alimena, Giuliana | |
| Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance | 2009 | Laura, Cannella; Massimo, Breccia; Stefanizzi, Caterina; Napoleone, Laura; Michela, Santopietro; Alimena, Giuliana | |
| Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results | 2009 | Roberto, Latagliata; Angela, Rago; Antonio, Spadea; Santoro, Cristina; Ida, Carmosino; Massimo, Breccia; Napoleone, Laura; Angelo, Fama; Francesca, Biondo; Paola, Volpicelli; Federico, Vozella; Stefanizzi, Caterina; Maria Concetta, Petti; Alimena, Giuliana; Mazzucconi, Maria Gabriella | |
| Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia | 2008 | Massimo, Breccia; Stefanizzi, Caterina; Laura, Cannella; Roberto, Latagliata; Anna Maria, Frustaci; Ida, Carmosino; Michelina, Santopietro; Alimena, Giuliana | |
| Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia | 2007 | Corrado, Girmenia; Eleonora, Russo; Ida, Carmosino; Massimo, Breccia; Francesco, Dragoni; Roberto, Latagliata; Sergio, Mecarocci; Salvatore Giacomo, Morano; Stefanizzi, Caterina; Alimena, Giuliana | |
| Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: AN IMMUNOMODULATORY EFFECT? | 2009 | Breccia, M; Cannella, L; Stefanizzi, Caterina; Carotti, A; Santopietro, M; Alimena, Giuliana | |
| Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib | 2008 | M., Breccia; Muscaritoli, Maurizio; L., Cannella; Stefanizzi, Caterina; A., Frustaci; Alimena, Giuliana | |
| Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia | In corso di stampa | Chisini, Marta; Stefanizzi, Caterina; Ceglie, Teresa; Raponi, Sara; Vozella, Federico; Colafigli, Gioia; Salaroli, Adriano; D'Angiò, Mariella; Mancini, Marco; Diverio, Daniela; Breccia, Massimo; Mancini, Francesca; Minotti, Clara; Trisolini, Silvia; Capria, Saveria; Testi, Anna Maria; Guarini, Anna; Latagliata, Roberto; De Propris, Maria Stefania; Foa, Roberto | |
| Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. | 2009 | Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana |